HORSHAM, Pa., June 19, 2017 /PRNewswire/ -- Researchers from DRUGSCAN® and INC Research® announced today that they will host a live, complimentary webinar titled, "Untangling methods to tamper with opioid formulations: Perspectives from the benchtop to the real world" on Wednesday June 28, 2017 from 12:00 PM to 1:00 PM EDT.
This webinar will feature interviews with recreational and dependent prescription opioid abusers offering a rare look into the manipulation techniques abusers use to prepare opioid tablets for routes of administration that provide a more powerful euphoria, such as intravenous or intranasal. The webinar will also discuss the laboratory experiments scientists conduct to evaluate the properties of abuse-deterrent formulations that are designed to resist these manipulation techniques.
"This candid session will focus on the abuser's extensive experiences with altering prescription opioids for unintended routes of administration" said Dr. Beatrice Setnik, Vice President of Scientific and Medical Affairs at INC Research "the experiences shared by these abusers can help inform laboratory and clinical evaluations of abuse-deterrent formulations"
For more information and to register for the webinar, click here: Registration. Availability will be limited. Please register by Friday June 23, 2017. The webinar will be recorded and available for on-demand viewing at the DRUGSCAN and INC Research websites.
About DRUGSCAN®
DRUGSCAN's CAT.one® laboratory-based manipulation and extraction studies are designed and conducted to produce data that can predict a product's strengths and weaknesses to physical and chemical manipulations as well as to support abuse-deterrent label claims. Employing state of the art technology and abuse-deterrent testing expertise, DRUGSCAN has been at the forefront of designing and conducting manipulation and extraction studies for many of the leading abuse-deterrent product developers in the US and around the world. To learn more about DRUGSCAN and their CAT.one capabilities, please visit www.drugscan.com or call 800-235-4890
About INC Research
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was ranked "Top CRO to Work With" among the top 10 global CROs in the 2017 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.
Media Contact: Greg Gironda[email protected]
Advertisement
This webinar will feature interviews with recreational and dependent prescription opioid abusers offering a rare look into the manipulation techniques abusers use to prepare opioid tablets for routes of administration that provide a more powerful euphoria, such as intravenous or intranasal. The webinar will also discuss the laboratory experiments scientists conduct to evaluate the properties of abuse-deterrent formulations that are designed to resist these manipulation techniques.
Advertisement
"This candid session will focus on the abuser's extensive experiences with altering prescription opioids for unintended routes of administration" said Dr. Beatrice Setnik, Vice President of Scientific and Medical Affairs at INC Research "the experiences shared by these abusers can help inform laboratory and clinical evaluations of abuse-deterrent formulations"
For more information and to register for the webinar, click here: Registration. Availability will be limited. Please register by Friday June 23, 2017. The webinar will be recorded and available for on-demand viewing at the DRUGSCAN and INC Research websites.
About DRUGSCAN®
DRUGSCAN's CAT.one® laboratory-based manipulation and extraction studies are designed and conducted to produce data that can predict a product's strengths and weaknesses to physical and chemical manipulations as well as to support abuse-deterrent label claims. Employing state of the art technology and abuse-deterrent testing expertise, DRUGSCAN has been at the forefront of designing and conducting manipulation and extraction studies for many of the leading abuse-deterrent product developers in the US and around the world. To learn more about DRUGSCAN and their CAT.one capabilities, please visit www.drugscan.com or call 800-235-4890
About INC Research
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was ranked "Top CRO to Work With" among the top 10 global CROs in the 2017 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.
Media Contact: Greg Gironda[email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/live-webinar-on-real-world-manipulation-techniques-used-by-prescription-opioid-drug-abusers-300474961.html
SOURCE DRUGSCAN
